Clinical Trials Browser

Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Neoplasm, Residual

NCT04506086 2025-05-18

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 4 Terminated

10 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03038230 2025-04-06

MCLA-117 in Acute Myelogenous Leukemia

Phase 1 Terminated

80 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04310592 2024-12-12

CYNK001AML01

Phase 1 Terminated

27 enrolled

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT03512197 2023-08-21

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Phase 3 Completed

511 enrolled 26 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04748848 2023-03-02

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Phase 1 Terminated

1 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1 Unknown

29 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03697707 2022-10-10

ADVANCE-II

Phase 2 Unknown

20 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Phase 1 Active not recruiting

15 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

NCT03441464 2022-02-25

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Phase 1/2 Terminated

9 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT01207388 2020-02-10

BLAST

Phase 2 Completed

116 enrolled 23 charts 2 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00560794 2015-01-26

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 2 Completed

21 enrolled 19 charts

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00172068 2009-12-23

MRD-1

Phase 2 Terminated

96 enrolled

Tumor-Agnostic

Neoplasm, Residual

Clinical Trials

CASSIOPEIA

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

FLAMINGO-01

ALPHA3

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

AMPLIFY-201

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

MCLA-117 in Acute Myelogenous Leukemia

CYNK001AML01

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

ADVANCE-II

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

BLAST

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

MRD-1